T Hickish
Overview
Explore the profile of T Hickish including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
2001
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hemandas A, Robson N, Hickish T, Talbot R
Colorectal Dis
. 2007 Jul;
10(4):386-9.
PMID: 17608754
Objective: The aim of this retrospective study was to assess the significance of incidental focal colonic lesions on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) scans in patients undergoing staging...
12.
Chau I, Cunningham D, Hickish T, Massey A, Higgins L, Osborne R, et al.
Ann Oncol
. 2007 Jan;
18(4):730-7.
PMID: 17237473
Background: To establish the recommended dose level (RDL) and to evaluate the efficacy and safety of gefitinib plus irinotecan in patients with advanced fluoropyrimidine-refractory colorectal cancer (CRC). Patients And Methods:...
13.
Chau I, Cunningham D, Russell C, Norman A, Kurzawinski T, Harper P, et al.
Br J Cancer
. 2006 Apr;
94(8):1107-15.
PMID: 16622436
Gastrin has been shown to be a growth stimulant in pancreatic cancer cells. Gastrazole is a potent and selective gastrin receptor antagonist. Two randomised blinded trials were conducted to assess...
14.
TRUMPER M, Ross P, Cunningham D, Norman A, Hawkins R, Seymour M, et al.
Eur J Cancer
. 2006 Feb;
42(7):827-34.
PMID: 16466913
The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above (> or =70) in comparison to younger patients....
15.
Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman A, et al.
Br J Cancer
. 2005 Jun;
92(11):1976-83.
PMID: 15928658
The purpose of the study was to establish the optimal dose of capecitabine (X) to be used within a multicentre, randomised study evaluating the potential roles of oxaliplatin (O) and...
16.
Chau I, Norman A, Cunningham D, Tait D, Ross P, Iveson T, et al.
Ann Oncol
. 2005 Feb;
16(4):549-57.
PMID: 15695501
Background: We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil (5-FU) against the standard bolus monthly regimen of...
17.
Donnelly J, Parham D, Hickish T, Chan H, Skene A
Breast
. 2004 Feb;
10(1):61-6.
PMID: 14965563
We observed that the axillary lymph nodes of some of our breast cancer patients who received neoadjuvant chemoendocrine therapy (NCT) showed evidence of scarring. The purpose of this study is...
18.
Saini A, Norman A, Cunningham D, Chau I, Hill M, Tait D, et al.
Br J Cancer
. 2003 Jun;
88(12):1859-65.
PMID: 12799627
We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen...
19.
Assersohn L, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, et al.
Eur J Cancer
. 2003 May;
39(8):1121-8.
PMID: 12736112
No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC)...
20.
Tebbutt N, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, et al.
Ann Oncol
. 2002 Oct;
13(10):1568-75.
PMID: 12377644
Background: This randomised study compared protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin C (MMC) in patients with advanced oesophago-gastric cancer. Patients And Methods: Two hundred and...